Next-Generation JAK Inhibition for Patients With Myelofibrosis

Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.

Ruben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.

During a live virtual event, John O. Mascarenhas, MD, discussed the PERSIST-1 and PERSIST-2 trials of pacritinib for patients with myelofibrosis with lower platelet counts.

During a live virtual event, John O. Mascarenhas, MD, discussed with participants the data supporting the use of pacritinib for patients with myelofibrosis. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.